Abstract S3-07: Letrozole plus dasatinib improves progression-free survival (PFS) in hormone receptor-positive, HER2-negative postmenopausal metastatic breast cancer (MBC) patients receiving first-line aromatase inhibitor (AI) therapy

D Paul; SJ Vukelja; FA Holmes; J Blum; KJ McIntyre; AR Kumar; DL Lindquist; CR Osborne; IJ Sanchez; JH Goldschmidt; Y Wang; L Asmar; Me Lee; N Wu; K Logie; J O'Shaughnessy

doi:10.1158/0008-5472.SABCS13-S3-07

Abstract S3-07: Letrozole plus dasatinib improves progression-free survival (PFS) in hormone receptor-positive, HER2-negative postmenopausal metastatic breast cancer (MBC) patients receiving first-line aromatase inhibitor (AI) therapy

D Paul
, SJ Vukelja
, FA Holmes
, J Blum
, KJ McIntyre
, AR Kumar
, DL Lindquist
, CR Osborne
, IJ Sanchez
, JH Goldschmidt
, Y Wang
, L Asmar
, Me Lee
, N Wu
, K Logie
, J O'Shaughnessy

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Cancer Research
Volume	73
DOIs	https://doi.org/10.1158/0008-5472.SABCS13-S3-07
State	Published - Dec 15 2013

Disciplines

Medicine and Health Sciences
Oncology
Surgery
Internal Medicine

Access to Document

10.1158/0008-5472.SABCS13-S3-07License: Unspecified

Cite this

Paul, D., Vukelja, SJ., Holmes, FA., Blum, J., McIntyre, KJ., Kumar, AR., Lindquist, DL., Osborne, CR., Sanchez, IJ., Goldschmidt, JH., Wang, Y., Asmar, L., Lee, M., Wu, N., Logie, K., & O'Shaughnessy, J. (2013). Abstract S3-07: Letrozole plus dasatinib improves progression-free survival (PFS) in hormone receptor-positive, HER2-negative postmenopausal metastatic breast cancer (MBC) patients receiving first-line aromatase inhibitor (AI) therapy. Cancer Research, 73. https://doi.org/10.1158/0008-5472.SABCS13-S3-07

Abstract S3-07: Letrozole plus dasatinib improves progression-free survival (PFS) in hormone receptor-positive, HER2-negative postmenopausal metastatic breast cancer (MBC) patients receiving first-line aromatase inhibitor (AI) therapy. / Paul, D; Vukelja, SJ; Holmes, FA et al.
In: Cancer Research, Vol. 73, 15.12.2013.

Research output: Contribution to journal › Article › peer-review

Paul, D, Vukelja, SJ, Holmes, FA, Blum, J, McIntyre, KJ, Kumar, AR, Lindquist, DL, Osborne, CR, Sanchez, IJ, Goldschmidt, JH, Wang, Y, Asmar, L, Lee, M, Wu, N, Logie, K & O'Shaughnessy, J 2013, 'Abstract S3-07: Letrozole plus dasatinib improves progression-free survival (PFS) in hormone receptor-positive, HER2-negative postmenopausal metastatic breast cancer (MBC) patients receiving first-line aromatase inhibitor (AI) therapy', Cancer Research, vol. 73. https://doi.org/10.1158/0008-5472.SABCS13-S3-07

Paul D, Vukelja SJ, Holmes FA, Blum J, McIntyre KJ, Kumar AR et al. Abstract S3-07: Letrozole plus dasatinib improves progression-free survival (PFS) in hormone receptor-positive, HER2-negative postmenopausal metastatic breast cancer (MBC) patients receiving first-line aromatase inhibitor (AI) therapy. Cancer Research. 2013 Dec 15;73. doi: 10.1158/0008-5472.SABCS13-S3-07

@article{987a2b496b13490c94fb2e62726c914a,

title = "Abstract S3-07: Letrozole plus dasatinib improves progression-free survival (PFS) in hormone receptor-positive, HER2-negative postmenopausal metastatic breast cancer (MBC) patients receiving first-line aromatase inhibitor (AI) therapy",

author = "D Paul and SJ Vukelja and FA Holmes and J Blum and KJ McIntyre and AR Kumar and DL Lindquist and CR Osborne and IJ Sanchez and JH Goldschmidt and Y Wang and L Asmar and Me Lee and N Wu and K Logie and J O'Shaughnessy",

note = "Abstracts: Thirty-Sixth Annual CTRC-AACR San Antonio Breast Cancer Symposium - Dec 10-14, 2013; San Antonio, TX Introduction Dasatinib inhibits the protein tyrosine kinase, Src, which can support the development of bone metastases in patients with ER+ breast cancer.",

year = "2013",

month = dec,

day = "15",

doi = "10.1158/0008-5472.SABCS13-S3-07",

language = "American English",

volume = "73",

journal = "Cancer Research",

issn = "1538-7445",

publisher = "American Association for Cancer Research",

}

TY - JOUR

T1 - Abstract S3-07: Letrozole plus dasatinib improves progression-free survival (PFS) in hormone receptor-positive, HER2-negative postmenopausal metastatic breast cancer (MBC) patients receiving first-line aromatase inhibitor (AI) therapy

AU - Paul, D

AU - Vukelja, SJ

AU - Holmes, FA

AU - Blum, J

AU - McIntyre, KJ

AU - Kumar, AR

AU - Lindquist, DL

AU - Osborne, CR

AU - Sanchez, IJ

AU - Goldschmidt, JH

AU - Wang, Y

AU - Asmar, L

AU - Lee, Me

AU - Wu, N

AU - Logie, K

AU - O'Shaughnessy, J

N1 - Abstracts: Thirty-Sixth Annual CTRC-AACR San Antonio Breast Cancer Symposium - Dec 10-14, 2013; San Antonio, TX Introduction Dasatinib inhibits the protein tyrosine kinase, Src, which can support the development of bone metastases in patients with ER+ breast cancer.

PY - 2013/12/15

Y1 - 2013/12/15

UR - https://cancerres.aacrjournals.org/content/73/24_Supplement/S3-07

U2 - 10.1158/0008-5472.SABCS13-S3-07

DO - 10.1158/0008-5472.SABCS13-S3-07

M3 - Article

SN - 1538-7445

VL - 73

JO - Cancer Research

JF - Cancer Research

ER -

Abstract S3-07: Letrozole plus dasatinib improves progression-free survival (PFS) in hormone receptor-positive, HER2-negative postmenopausal metastatic breast cancer (MBC) patients receiving first-line aromatase inhibitor (AI) therapy

Disciplines

Access to Document

Other files and links

Cite this